H
Hao Yin
Researcher at Wuhan University
Publications - 67
Citations - 10720
Hao Yin is an academic researcher from Wuhan University. The author has contributed to research in topics: Genome editing & CRISPR. The author has an hindex of 38, co-authored 65 publications receiving 8959 citations. Previous affiliations of Hao Yin include Anschutz Medical Campus & Massachusetts Institute of Technology.
Papers
More filters
Journal ArticleDOI
Non-viral vectors for gene-based therapy
Hao Yin,Rosemary Lynn Kanasty,Ahmed A. Eltoukhy,Arturo J. Vegas,J. Robert Dorkin,Daniel G. Anderson +5 more
TL;DR: The biological barriers to gene delivery in vivo are introduced and recent advances in material sciences, nanotechnology and nucleic acid chemistry that have yielded promising non-viral delivery systems are discussed, some of which are currently undergoing testing in clinical trials.
Journal ArticleDOI
Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype
Hao Yin,Wen Xue,Sidi Chen,Roman L. Bogorad,Eric Benedetti,Markus Grompe,Victor Koteliansky,Phillip A. Sharp,Tyler Jacks,Daniel G. Anderson +9 more
TL;DR: In this article, the authors demonstrate CRISPR-Cas9-mediated correction of a Fah mutation in hepatocytes in a mouse model of the human disease hereditary tyrosinemia.
Journal ArticleDOI
Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo
Hao Yin,Chun-Qing Song,Joseph R. Dorkin,Lihua Julie Zhu,Yingxiang Li,Qiongqiong Wu,Angela I. Park,Junghoon Yang,Sneha Suresh,Aizhan Bizhanova,Ankit Gupta,Mehmet Fatih Bolukbasi,Stephen Walsh,Roman L. Bogorad,Guangping Gao,Zhiping Weng,Yizhou Dong,Victor Koteliansky,Victor Koteliansky,Scot A. Wolfe,Robert Langer,Wen Xue,Daniel G. Anderson +22 more
TL;DR: The delivery strategy is applied to a mouse model of human hereditary tyrosinemia and it is shown that the treatment generated fumarylacetoacetate hydrolase (Fah)-positive hepatocytes by correcting the causative Fah-splicing mutation and rescued disease symptoms such as weight loss and liver damage.
Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype
Hao Yin,Wen Xue,Sidi Chen,Roman L. Bogorad,Eric Benedetti,Markus Grompe,Victor Koteliansky,Phillip A. Sharp,Tyler Jacks,Daniel G. Anderson +9 more
TL;DR: This study indicates that CRISPR-Cas9–mediated genome editing is possible in adult animals and has potential for correction of human genetic diseases.
Journal ArticleDOI
CRISPR-mediated direct mutation of cancer genes in the mouse liver
Wen-Bin Xue,Sidi Chen,Hao Yin,Tuomas Tammela,Thales Papagiannakopoulos,Nikhil S. Joshi,Wenxin Cai,Gillian R. Yang,Roderick T. Bronson,Denise G. Crowley,Feng Zhang,Daniel G. Anderson,Phillip A. Sharp,Tyler Jacks +13 more
TL;DR: This study demonstrates the feasibility of direct mutation of tumour suppressor genes and oncogenes in the liver using the CRISPR/Cas system, which presents a new avenue for rapid development of liver cancer models and functional genomics.